# cleerly

Aiming for a New Standard in Diagnosing Coronary Artery Disease

THE INVESTMENT THESIS

Cardiovascular diseases are the leading cause of death for men and women in the United States, with more than 800,000 deaths per year. Fifty percent of people who suffer from a heart attack have had no prior symptoms. Having spent over a decade performing clinical trials, Cleerly's technology identifies findings beyond symptoms that increase a person's risk of heart attack.

3 GOOD HEALTH AND WELL-BEING

SEEING MORE OF WHAT MATTERS

Current diagnostic approaches in cardiovascular disease are poor predictors of who is at high risk of having a heart attack. Cleerly's technology can help create a new standard of care for cardiovascular disease to prevent millions of heart attacks worldwide. Cleerly's technology can improve diagnosis, prognosis, and treatment by using an end-to-end machine learning framework to analyse coronary computed tomography angiography (CCTA) scans. Cleerly Coronary enables comprehensive quantification and characterization of plaque buildup in each of the heart arteries, using a non-invasive, AI-driven approach to identify and distinguish the features of plaques that may cause heart attacks. By helping to provide each stakeholder — from the imaging physician to the patient — the information they need, Cleerly's product aims to drastically improve the identification of at-risk patients for early treatment and prevention of heart attacks.

DEVELOPMENTAL PROGRESS

Pre-clinical — Clinical trials — Approval — Commercialization